Fiasp®

DRUG3 trials

Sponsors

Adocia, Novo Nordisk A/S, Texas Diabetes & Endocrinology, P.A.

Conditions

Diabetes Mellitus, Type 1Type 1 Diabetes MellitusType1 Diabetes Mellitus

Phase 1

A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump

CompletedNCT03179332

AdociaType1 Diabetes Mellitus

Start: 2017-06-20End: 2017-09-27Updated: 2017-12-12

Phase 3

FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

CompletedNCT03977727

Texas Diabetes & Endocrinology, P.A.Type 1 Diabetes Mellitus

Start: 2019-06-11End: 2020-04-20Updated: 2020-09-29

Unknown Phase

Effect of Fiasp® in Type 1 Diabetes Treatment

CompletedNCT03895515

Novo Nordisk A/SDiabetes Mellitus, Type 1

Start: 2020-01-03End: 2020-12-21Updated: 2022-04-07

Related Papers

Fast-Acting Insulin Aspart in Patients with Type 1 Diabetes in Real-World Clinical Practice: A Noninterventional, Retrospective Chart and Database Study.

2023-07-141 citations

Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study

Diabetes Technology & Therapeutics2020-10-2236 citations